When Amazon envisioned Alexa, an AI-powered, voice-activated customer recommendation system, it was a feat that required machine learning and massive amounts of data to provide answers to conversational queries quickly, even in a noisy environment. Now, the same data analysis
Since the start of the pandemic, many companies looked for ways to bolster mental health coverage, but there’s still a disconnect between HR administrators and employees, according to a recent survey conducted by mental health startup Lyra Health. About half
The insurtech market, which is characterized by fierce competition, recently saw a new entrant: Circulo. Co-founded by Sean Lane — CEO of another health tech startup Olive — the new Medicaid managed care company launched last month with $50 million
A group of health insurers are joining forces to help get older Americans in underserved communities vaccinated with the Covid-19 vaccine. Members of America’s Health Insurance Plans, a national payer association, and Blue Cross Blue Shield Association, a federation of
Amgen, which is looking to bolster its cancer drug pipeline and build its presence in Asia, is acquiring Five Prime Therapeutics in a $1.9 billion deal that checks off both goals. On Thursday, Amgen announced it has agreed to
U.S. Supreme Court justices on Monday questioned lawyers for Arthrex Inc., Smith & Nephew and the U.S. government on the constitutionality of the country’s patent tribunal, in a case that could eradicate a key tool for generic and technology companies
Essential to the future of cancer immunotherapies is a digital health infrastructure that can support reliable, secure and compliant data collection from disparate systems and devices. As more and more immuno-oncology (IO) treatments come to market, biopharma will require data
When Takeda Pharmaceutical and Ovid Therapeutics began working together four years ago, the partners aimed to share in the development of a drug with the potential to treat rare forms of epilepsy. The partners are ending the alliance, but Takeda
The FDA almost never reveals its thinking about a drug prior to issuing a regulatory decision, and when that decision is a rejection the letter to the company is always confidential. Brainstorm Cell Therapeutics hasn’t even submitted its amyotrophic
Hillrom is calling off a planned acquisition of cardiac monitor-maker Bardy Diagnostics, saying the closing conditions of the deal had not been satisfied. The Chicago-based medical technology company announced its decision on Monday after Medicare Administrative Contractor Novitas Solutions slashed